US3852433A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Uridine-5-monophosphate compositions
Assignee: Yamasa Shoyu KK
•
Filing: 1973-04-06
•
Granted: 1974-12-03
•
Expires: 1993-04-06
Abstract
Abstract Pharmaceutical compositions characterized by accelerating action for glucuronide formation comprising uridine-5''-monophosphate or its pharmaceutically acceptable salt in admixture with pharmaceutical carriers.
Inventors
- 👤 S Tamura
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
31 words
A PHARMACEUTICAL COMPOSITION AS AN ACCELERATOR FOR GLUCURONIDE FORMATION IN DOSAGE UNIT FORM COMPRISING AN EFFECTIVE AMOUNT OF URIDINE-5''-MONOPHOSPHATE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AS ACTIVE INGREDIENT AND A PHARMACEUTICAL CARRIER.
Claim 2
Dependent Claim
31 words
A PHARMACEUTICAL COMPOSITION AS AN ACCELERATOR FOR GLUCURONIDE FORMATION IN DOSAGE UNIT FORM COMPRISING AN EFFECTIVE AMOUNT OF URIDINE-5''-MONOPHOSPHATE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AS ACTIVE INGREDIENT AND A PHARMACEUTICAL CARRIER.
Claim 3
Dependent Claim
24 words
The pharmaceutical composition according to claim 1, wherein each dosage unit contains from 50 mg to 500 mg of uridine-5''-monophosphate as its sodium salt.
Claim 4
Dependent Claim
25 words
The pharmaceutical composition according to claim 1, further containing a substance selected from the group consisting of methionine, cysteine and glutathione as a biochemical antidote.
Claim 5
Dependent Claim
23 words
The pharmaceutical composition according to claim 1, further containing a vitamin selected from the group consisting of group B vitamins and vitamin C.
Claim 6
Dependent Claim
23 words
The pharmaceutical composition according to claim 3, further containing a vitamin selected from the group consisting of group B vitamins and vitamin C.
Claim 7
Independent Claim
40 words
A method of administering to humans, a pharmaceutical composition as an accelerator for glucuronide formation in dosage unit form comprising an effective amount of uridine-5''-monophosphate or its pharmaceutically acceptable salt, as the accelerator for glucuronide formation, and a pharmaceutical carrier.
Claim 8
Independent Claim
40 words
A method of administering to humans, a pharmaceutical composition as an accelerator for glucuronide formation in dosage unit form comprising an effective amount of uridine-5''-monophosphate or its pharmaceutically acceptable salt, as the accelerator for glucuronide formation, and a pharmaceutical carrier.
Claim 9
Dependent Claim
22 words
A method according to claim 6 wherein each dosage unit contains 50 mg. to 500 mg. of uridine-5''-monophosphate as its sodium salt.
Claim 10
Dependent Claim
28 words
A method according to claim 7 wherein the pharmaceutical composition further contains a substance selected from the group consisting of methionine, cysteine and glutathione as a biological antidote.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1977-12-02 | 1978-06-03 | 1978-12-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1981-12-02 | 1982-06-03 | 1982-12-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1985-12-02 | 1986-06-03 | 1986-12-03 | $7700.00 | Window Closed / Lapsed |